Clinical Trials in Bulgaria

• Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active Psoriatic Arthritis (PsA) who are Naïve to Biologic… Ended
  2023-506256-25-00 Phase III Active Psoriatic Arthritis Bristol-Myers Squibb Services Unlimited Company
• A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP Ended
  2023-508838-33-00 Phase III Chronic Myeloid Leukemia Novartis Pharma AG
• A randomized, double-blind, Phase III Study of AZD9833 plus CDK4/6 inhibitor in patients with metastatic breast cancer with detectable ESR1 … Ended
  2023-503990-39-00 Phase III Estrogen Receptor-Positive, HER-2 negative Advanced Breast C… AstraZeneca AB
• Phase 3 Randomized Study of Talazoparib with Enzalutamide in Men with DDR Gene Mutated mCSPC Ended
  2024-510809-28-00 Phase III Metastatic Castration-sensitive Prostate Cancer Pfizer Inc.
• The STARBOARD Study: Phase 3 Study of Encorafenib and Binimetinib Plus Pembrolizumab in BRAF V600E/K Mutation-Positive Metastatic or Unresec… Ended
  2024-512038-13-00 Phase III Metastatic or unresectable locally advanced BRAF V600E/K mut… Pfizer Inc.
• A study to learn if dapirolizumab pegol is safe and works long-term in people with systemic lupus erythematosus Ended
  2023-506368-14-00 Phase III Systemic lupus erythematosus (SLE) UCB Biopharma
• A Study of the Efficacy and Safety of Guselkumab in Participants with Active Psoriatic Arthritis Ended
  2023-504734-21-00 Phase III Psoriatic arthritis (PsA) Janssen - Cilag International
• Guselkumab versus Placebo for the Treatment of Psoriatic Arthritis Axial Disease in Bio-naive Participants Ended
  2023-504716-15-00 Phase IV Psoriatic Arthritis Janssen - Cilag International
• Proof-of-concept study for SAR441344 (frexalimab) in relapsing multiple sclerosis. Ended
  2024-513527-17-00 Phase II Multiple Sclerosis Sanofi-Aventis Recherche & Developpement
• A Randomised, Double-Blind, Phase III Study of AZD9833 plus Palbociclib versus Anastrozole plus Palbociclib in Patients with ER-Positive HER… Ended
  2023-503995-26-00 Phase III Estrogen Receptor-Positive, HER2-Negative Advanced Breast Ca… AstraZeneca AB
• A Study of Atezolizumab with Lenvatinib or Sorafenib versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously … Ended
  2023-503229-21-00 Phase III Unresectable hepatocellular carcinoma (HCC) F. Hoffmann-La Roche AG
• Phase 3 Trial of Perioperative EV and Pembro vs. Chemo in Cis-E MIBC Ended
  2023-505615-21-00 Phase III Muscle Invasive Bladder Cancer Merck Sharp & Dohme LLC
• A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Alone and in Combination With Ruxolitinib in Participants Wit… Ended
  2023-507274-40-00 Phase I (Other) Myelofibrosis AbbVie Deutschland GmbH & Co. KG
• A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive… Ended
  2023-503568-18-00 Phase III Early human epidermal growth factor receptor 2 (HER2) positi… F. Hoffmann-La Roche AG
• A study comparing current available therapies with imetelstat for the treatment of intermediate-2 or high-risk MF who are not responding to … Ended
  2023-509120-17-00 Phase III Myelofibrosis Geron Corp.
• A Study of TL-895 in Myelofibrosis, Indolent Systemic Mastocytosis, Monoclonal Mast Cell Activation Syndrome, or Non-Monoclonal Mast Cell Ac… Ended
  2024-514467-26-00 Phase II Indolent Systemic Mastocytosis Telios Pharma Inc.
• Research study on whether semaglutide works in people with non-alcoholic steatohepatitis (NASH) Ended
  2023-506962-30-00 Phase III Non-alcoholic steatohepatitis (NASH) Novo Nordisk A/S
• A Study of Osimertinib with or without Chemotherapy versus Chemotherapy alone as neoadjuvant therapy for Patients with Epidermal Growth Fact… Ended
  2022-502606-33-00 Phase III Patients with histologically or cytologically documented non… AstraZeneca AB
• A study of patients with colorectal cancer that have a genetic abnormality in the BRAF gene taking encorafenib plus cetuximab with or withou… Ended
  2023-509405-77-00 Phase III Colorectal cancer (BRAF V600E-mutant mCRC) Pfizer Inc.
• Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed … Ended
  2023-504959-27-00 Phase III Participants with Limited Stage-Small Cell Lung Cancer, who … Merck Sharp & Dohme LLC
• A Study to compare the efficacy of Risankizumab and Utsekinumab in Subjects with Moderately to Severe Active Crohns Disease Ended
  2022-501645-70-00 Phase III Crohns Disease Abbvie Deutschland GmbH & Co. KG
• A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Ocrelizumab in Adult Patients with Primary Progressive Multiple Sc… Ended
  2022-502611-10-00 Phase III Primary Progressive Multiple Sclerosis (PPMS) F. Hoffmann-La Roche AG
• A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Teriflunomide in Adult Patients with Relapsing Multiple Sclerosis Ended
  2022-502618-95-00 Phase III Relapsing multiple sclerosis (RMS) F. Hoffmann-La Roche AG
• A study of safety and efficacy of NBI-74788 in Classic Congenital Adrenal Hyperplasia Ended
  2023-509171-16-00 Phase III Classic Congenital Adrenal Hyperplasia (CAH) Neurocrine Biosciences Inc.

Showing 529–552 of 869 trials